Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 25, 2005

View Archived Issues

A novel EphA2-targeting antibody conjugated to MMAF reverses tumor growth

Takeda offers six-month development update

Enrollment complete in study of ETHOS I stent

Anti-TNF-alpha vaccine works in arthritic mice

Fractalkine identified as a novel target for the treatment of atherosclerosis

Obestatin: a newly identified hormone that suppresses appetite

Neose Technologies receives milestone payment from Novo Nordisk

Acambis begins pivotal program for ChimeriVax-JE

Preliminary results from phase I study of IPL-455903

Sinovac cleared to advance pandemic influenza vaccine into Chinese clinical testing

Wex preparing IND for Tectin

First patient dosed in phase II study of VRX-496 for HIV

FDA approves updated labeling for Lexiva

Research objective met in Arius and Protein Design Labs' collaboration

CF-101 demonstrates efficacy in phase II rheumatoid arthritis trial

Liposome entrapped c-raf antisense oligonucleotide assessed in phase I study

Flurizan taken beyond 1 year improved cognition in Alzheimer's disease patients

D3 antagonists may provide a useful adjunct to levodopa therapy

T-817MA improves beta-amyloid-induced learning deficits in rats

Shire submits BLA for Elaprase for Hunter's syndrome

GlaxoSmithKline seeks Japanese approval for fondaparinux sodium

Theravance prepares and tests 5-HT4 receptor agonists for gastrointestinal disorders

Recent patents disclose novel agents for the treatment of endocrine-related disorders

Belimumab activity, safety revealed in phase II rheumatoid arthritis trial

Animal studies support clinical evaluation of TACI-Ig

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...